MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14740338.2024.2430307

Медицинская библиотека · Expert opinion on drug safety · 2024

Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA Adverse Event Reporting System.

Cai Li-Li, Zhou Hong, Wu Na-Mei, Hong Li-Mian, Lin Zhi-Hang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Aztreonam was approved by the FDA for treating Gram-negative infections, including metallo-β-lactamase producers. This study extensively evaluated aztreonam-related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS) database for a better understanding of toxicities.

METHODS

The signals of aztreonam-related AEs were quantified using disproportionality analyses, like reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms.

RESULTS

Among the 18,182,912 records retrieved from the FAERS 11,627 cases were identified where aztreonam was the primary suspect drug. A total of 127 preferred terms with significant disproportionality that simultaneously met the criteria of all algorithms were retained. Unexpected safety signals such as cholestatic liver injury, hypoprothrombinemia, hemoptysis, pulmonary hemorrhage, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis and so on may also manifest in adults, particularly in elderly patients. The median onset time for AEs related to intravenous aztreonam was 4 days, compared to a year after the initiation of inhaled aztreonam.

CONCLUSIONS

Our study identified potential new adverse event signals and offered a thorough understanding of aztreonam's safety profiles. This information is crucial for enhanced cliggnical monitoring and risk assessment, aiding healthcare professionals in tailoring their approach.

Для цитирования: Cai Li-Li, Zhou Hong, Wu Na-Mei, Hong Li-Mian, Lin Zhi-Hang. Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA Adverse Event Reporting System.. Expert opinion on drug safety. 2024. DOI: 10.1080/14740338.2024.2430307.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.